Hyperuricemia – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032

 Hyperuricemia refers to an elevated concentration of uric acid in the bloodstream, with levels surpassing the standard upper limit of 6.8mg/dL. When uric acid content reaches 7 mg/dL or more, it is considered to be saturated, and this can lead to the emergence of symptoms. This elevation in uric acid arises from an excess production of uric acid, a reduced ability to eliminate uric acid or a combination of these two processes. The elevated uric acid levels can also be observed in conditions involving rapid breakdown of cells, such as hemolysis, rhabdomyolysis, and tumor lysis, which lead to accelerated purine degradation. Additionally, reduced excretion of uric acid can result from issues like renal insufficiency and metabolic acidosis. Hyperuricemia is linked to the development of gout, a condition characterized by the accumulation of uric acid in the blood and tissues, as well as nephrolithiasis (formation of kidney stones).

Urate Overproduction:

1.       Consumption of diets rich in purines

2.       Disorders in purine metabolism, such as hypoxanthine phosphoribosyltransferase (HPRT) deficiency and overactivity of phosphoribosylpyrophosphate (PRPP) synthetase

3.       Cellular breakdown or turnover in conditions like lymphoproliferative diseases, myeloproliferative disease, polycythemia vera, Paget disease, psoriasis, tumor lysis, hemolysis, rhabdomyolysis, and during exercise

Decreased Uric Acid Excretion:

1.       Acute or chronic kidney disease

2.       Acidosis (lactic acidosis, ketoacidosis)

3.       Dehydration

4.       Medications or toxins (diuretics, niacin, pyrazinamide, ethambutol, cyclosporin, beryllium, salicylates, lead, alcohol)

5.       Conditions like sarcoidosis, hyperparathyroidism, hypothyroidism, Bartter syndrome, and Down syndrome

Gout, characterized by an accumulation of uric acid leading to the formation of urate monohydrate crystals within joints, is a metabolic disorder. Crystallization is facilitated in acidic and cold environments, causing more crystals to form in peripheral joints like the big toe. Gout predominantly affects males, with a male-to-female ratio of 4:1. Elevated uric acid levels can precede the clinical onset of gout by a decade or more. Many individuals with hyperuricemia remain symptom-free and do not require medical intervention, as they may never experience gout or nephrolithiasis. Medication's potential drawbacks and expenses often outweigh the benefits for these asymptomatic cases. Urate-lowering drugs (such as Allopurinol, Probenecid, and Rasburicase) are only recommended for asymptomatic patients undergoing cytolytic therapy for malignancies, aiming to prevent tumor lysis syndrome.

·       In the United States, hyperuricemia has been observed in 14.6% of the population, which accounts for an estimated 32.5 million individuals.

Thelansis’s “Hyperuricemia Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Hyperuricemia treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

KOLs insights of Hyperuricemia across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.

Hyperuricemia Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.

Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.

Read more: Hyperuricemia – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032